These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 37772558)

  • 1. Comprehensive Analysis of
    Liu J; Zhu B; Chen J; Cao Y
    Anticancer Res; 2023 Oct; 43(10):4491-4509. PubMed ID: 37772558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer.
    Yang Z; Xu D; Ye X; Lin X; Zhang M; Su Y; Xie Q; Ni W
    Biomed Res Int; 2022; 2022():3924400. PubMed ID: 35252444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
    Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
    Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA WAC-AS1 expression in human tumors correlates with immune infiltration and affects prognosis.
    Wang Y; Gong H; Cao Y
    Hereditas; 2023 May; 160(1):26. PubMed ID: 37248547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ADAMTSL2 is a potential prognostic biomarker and immunotherapeutic target for colorectal cancer: Bioinformatic analysis and experimental verification.
    Huang Z; Hu X; Wei Y; Lai Y; Qi J; Pang J; Huang K; Li H; Cai P
    PLoS One; 2024; 19(5):e0303909. PubMed ID: 38814950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker.
    Zhang W; Wu C; Zhou K; Cao Y; Zhou W; Zhang X; Deng D
    Front Genet; 2022; 13():993438. PubMed ID: 36685895
    [No Abstract]   [Full Text] [Related]  

  • 7. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Pan-Cancer Analysis of KIF18A as a Marker for Prognosis and Immunity.
    Liu T; Yang K; Chen J; Qi L; Zhou X; Wang P
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. POC1A, prognostic biomarker of immunosuppressive microenvironment in cancer.
    Zhao Q; Gao S; Chen X; Zhu X
    Aging (Albany NY); 2022 Jun; 14(12):5195-5210. PubMed ID: 35748773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Comprehensive Bioinformatic Analysis for Identification of Myeloid-Associated Differentiation Marker as a Potential Negative Prognostic Biomarker in Non-Small-Cell Lung Cancer.
    Zhou M; Chen Y; Gu X; Wang C
    Pathol Oncol Res; 2022; 28():1610504. PubMed ID: 36061144
    [No Abstract]   [Full Text] [Related]  

  • 11. A Comprehensive Pan-Cancer Analysis of 33 Human Cancers Reveals the Immunotherapeutic Value of Aryl Hydrocarbon Receptor.
    Mo Z; Li P; Cao Z; Zhang S
    Front Immunol; 2021; 12():564948. PubMed ID: 34290693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker.
    Xu Y; Lin Z; Ji Y; Zhang C; Tang X; Li C; Liu T
    Eur J Med Res; 2023 Oct; 28(1):438. PubMed ID: 37848933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Pan-Cancer Analysis Reveals the Prognostic and Immunotherapeutic Value of Stanniocalcin-2 (STC2).
    Jiang ZH; Shen X; Wei Y; Chen Y; Chai H; Xia L; Leng W
    Front Genet; 2022; 13():927046. PubMed ID: 35937984
    [No Abstract]   [Full Text] [Related]  

  • 14. Secreted phosphoprotein 1 as a potential prognostic and immunotherapy biomarker in multiple human cancers.
    Zeng P; Zhang X; Xiang T; Ling Z; Lin C; Diao H
    Bioengineered; 2022 Feb; 13(2):3221-3239. PubMed ID: 35067176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RecQ mediated genome instability 2 (
    Wei W; Ying X; Chen L; Sun Q; Lu X; Xia Y; Xu R; Zhu Z; Zhang D; Tang Q; Li L; Xie J; Yu H
    Aging (Albany NY); 2022 May; 14(9):4107-4136. PubMed ID: 35552266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive analysis reveals TSPEAR as a prognostic biomarker in colorectal cancer.
    Xue D; Peng H; Li Z; Xu J; Ma H; Dang Y; Li F; Wang G; Sun Q
    J Cancer; 2024; 15(3):809-824. PubMed ID: 38213725
    [No Abstract]   [Full Text] [Related]  

  • 17. Pan-cancer analysis identifies migrasome-related genes as a potential immunotherapeutic target: A bulk omics research and single cell sequencing validation.
    Qin Y; Yang J; Liang C; Liu J; Deng Z; Yan B; Fu Y; Luo Y; Li X; Wei X; Li W
    Front Immunol; 2022; 13():994828. PubMed ID: 36405728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pan-cancer analyses of clinical prognosis, immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data.
    Shen C; Fu C; Suo Y; Li K; Zhang Z; Yang S; Zhang Y; Lin Y; Li Z; Wu Z; Huang S; Chen H; Fan Z; Hu H
    Heliyon; 2023 Jun; 9(6):e16897. PubMed ID: 37346342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prognostic and immunological analysis of 7B-containing Kelch structural domain (KLHDC7B) in pan-cancer: a potential target for immunotherapy and survival.
    Ding J; Ji X; Liu L; Chen DZ; Luo N; Yu XT; Guo F
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7857-7876. PubMed ID: 37039902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Systematic Immune and Prognostic Analysis of CD48 Interaction with Tumor Microenvironment in Pan-Cancer.
    He M; Yu J; Chen S; Mi H
    Int J Gen Med; 2023; 16():5255-5269. PubMed ID: 38021043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.